Bristol Myers Rolls Out Long-Term Data For Mavacamten In Heart Disease

Bristol Myers Squibb & Co (NYSE:BMY) has announced long-term data from a mavacamten study acquired via a $13 billion MyoKardia buyout.
Heart patients who received mavacamten in a cohort of the long-term MAVA-LTE study saw significant reductions in median levels of a hormone called NT-proBNP (58% at week 24 and 67% at week 48).
Bristol Myers called this a “sustained reduction,” adding that improvements in left ventricular relaxation and diastolic function were also seen. However, no significant changes were observed in left-ventricular stroke volume.
Mavacamten was “well-tolerated” in the long-term study, Bristol Myers said. However, nine patients paused their treatment because left ventricular ejection fractions were too low.
Eight of them resumed treatment at a lower dose after recovery, while one discontinued the trial permanently.
Price Action: BMY shares closed at $59.43 on Friday.